Every Form 4 that PROTO LABS, INC. (PRLB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PRLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRLB filings page.
Proto Labs Inc (PRLB) Chief Financial Officer Daniel Schumacher sold 5,000 shares of common stock on September 24, 2026, at a weighted average price of $95.3209 per share across multiple transactions; sale prices ranged from $95.00 to $95.65. The sale was executed under a Rule 10b5-1 trading plan adopted on June 5, 2026. He directly held 35,019 shares after the sale.
Proto Labs Inc (PRLB) reported that Chief Financial Officer Daniel Schumacher sold a total of 5,000 shares of common stock in open-market transactions on September 16–17, 2026 under a Rule 10b5-1 trading plan. The September 17 sale of 4,900 shares used a weighted-average price with trades between $85.00 and $85.50 per share.
Proto Labs Inc director Sven Wehrwein reported selling a total of 2,000 shares of common stock in open-market transactions on June 2, 2026. The shares were sold in two blocks: 500 shares at $78.38 per share and 1,500 shares at a weighted average price of $76.9067 per share. He continues to hold more than 32,000 shares directly after these sales, indicating this was a relatively small portion of his overall reported holdings.
Proto Labs Inc President and CEO Krishna Suresh reported a tax-related share disposition. On May 23, 2026, 1,247 shares of Common Stock were used in a tax-withholding disposition at $71.36 per share, a method of paying tax liability with shares rather than cash. After this non‑market transaction, Suresh directly holds 30,147 shares of Proto Labs common stock.
Proto Labs Inc Chief Financial Officer Daniel Schumacher reported a routine tax-related share disposition. On May 20, 2026, 255 shares of Common Stock were withheld at $71.13 per share to cover tax obligations, leaving him with 45,019 directly held shares.
Proto Labs Inc reported that Chief Commercial Officer Bernardo Parlange received new equity compensation. He was granted 2,109 shares of common stock as restricted stock units, plus options on 3,789 shares of common stock at an exercise price of $71.13 per share. The RSUs and the underlying shares from the option grant vest in four equal annual installments, with 25% vesting on May 20, 2027 and on each May 20 thereafter until fully vested. Following these awards, the filing shows 2,109 common shares and options for 3,789 shares held directly.
Black Archie C. reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Archie C. Black received an equity award of 2,210 deferred stock units on Common Stock. These units were granted at no cash cost and increase his direct holdings to 28,428 shares. The units vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Shareholders, and must be retained until his service on the Board of Directors ends.
Chand Sujeet reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Sujeet Chand received an award of 2,210 shares of Common Stock as a grant with no cash price per share. These are deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders.
The units must be retained until Chand’s service on the company’s Board of Directors ends, underscoring their role as long-term director compensation. After this award, Chand directly holds 26,863 shares of Proto Labs common stock.
Proto Labs Inc director Moonhie Chin acquired 2,210 shares of common stock as a stock award. The Form 4 shows this equity grant at a price of $0.0000 per share on May 19, 2026, increasing Chin’s direct holdings to 22,306 shares.
The footnote explains these are deferred stock units that vest in full on the earlier of the first anniversary of the grant date or the Company’s 2027 Annual Meeting of Shareholders, and must be retained until Chin’s service on the Board of Directors ends.
Gawlick Rainer reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Rainer Gawlick received an award of 2,210 deferred stock units tied to common stock. The units were granted at no cash cost and increase his direct holdings to 46,093 common shares and units.
The deferred stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders, but must be retained until his service on the Board of Directors ends. This filing reflects routine, compensation-related equity, not an open-market purchase or sale.
WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director Sven Wehrwein received an equity award of 2,210 deferred stock units on Common Stock. The award was granted at no cash cost per share and is a form of board compensation rather than an open-market purchase.
These deferred stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders, and must be held until his service on the Board of Directors ends. Following this grant, Wehrwein directly holds 34,505 shares of Proto Labs common stock.
Proto Labs director Donald G. Krantz reported an acquisition of company stock through a compensation grant. He received 2,210 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, reflecting an equity award rather than a market purchase.
These restricted stock units vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Shareholders. After this award, Krantz directly holds 26,863 shares of Proto Labs common stock.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported a series of transactions in company common stock. On May 11–12, 2026, he sold a total of 23,463 shares in open-market sales at weighted average prices generally between about $67 and $71 per share, under a pre-arranged Rule 10b5-1 trading plan adopted August 15, 2025. Over the same two days, he exercised employee stock options covering 14,960 shares at exercise prices of $33.52, $33.84, $39.61 and $59.40 per share, converting derivative awards into common stock. Following these transactions, he directly holds 18,683 Proto Labs shares.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 200 shares of Common Stock at $70.00 per share in an open-market sale and exercised stock options to acquire 200 shares at strike prices of $33.52 and $33.84 per share.
The filing shows these trades were made under a pre-arranged 10b5-1 trading plan adopted on August 15, 2025. Following the transactions, he holds 27,186 Common Stock shares directly and continues to hold employee stock options, including grants with remaining balances of 7,455 and 7,612 options that vest annually starting on specified February 13 vesting dates.
Krishna Suresh reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director and President & CEO Suresh Krishna reported equity awards on February 25, 2026. He received 24,383 employee stock options and a grant of 13,373 shares of common stock at a price of $0.00 per share as compensation awards. The related restricted stock units vest 25% on February 25, 2027 and on each February 25 thereafter until fully vested.
Proto Labs Inc Chief Financial Officer Daniel Schumacher reported equity compensation changes. He received a grant of 5,605 employee stock options and 3,074 shares of common stock, both at a price of $0.00 per share, increasing his direct holdings. A separate disposition of 504 common shares at $62.63 per share was made to cover tax withholding obligations, rather than an open-market sale. The restricted stock units underlying the common stock grant vest in four equal annual installments, with 25% vesting on February 25, 2027 and on each February 25 thereafter until fully vested.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported equity compensation transactions on February 25, 2026. He received a grant of 4,404 employee stock options and a separate award of 2,415 shares of common stock, both recorded at a price of $0.00 as they are compensation grants.
The filing also shows a disposition of 531 shares of common stock at $62.63 per share classified as a tax-withholding transaction, used to satisfy tax obligations related to the award. After these transactions, his direct common stock holdings totaled 27,186 shares. Footnotes state that 25% of the restricted stock units vest on February 25, 2027, with additional 25% portions vesting on each February 25th thereafter until fully vested.
Proto Labs Inc Chief Technology & AI Officer Marc Kermisch reported equity awards on February 25, 2026. He acquired an employee stock option for 5,095 shares at an exercise price of $0.00 per share and a grant of 2,795 shares of common stock.
The filing explains that the common stock reflects restricted stock units, with 25% of the shares scheduled to vest on February 25, 2027, and additional 25% tranches vesting on each February 25 thereafter until fully vested. Following the award, he directly owned 6,513 shares of common stock.
Proto Labs Inc Chief Financial Officer Daniel Schumacher reported a Form 4 transaction involving company common stock. On February 13, 2026, he disposed of 1,267 shares of Proto Labs common stock at $67.52 per share to satisfy tax obligations by delivering shares. After this tax-withholding disposition, he directly owned 42,704 common shares of Proto Labs.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported two transactions in company common stock. On February 17, 2026, he sold 5,000 shares in an open-market transaction at a weighted average price of $66.463 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 25,302 shares directly held afterward.
Earlier, on February 13, 2026, he disposed of 1,540 shares at $67.52 per share to cover tax obligations through a stock withholding transaction, after which his direct holdings were 30,302 shares. The open-market sale prices ranged from $66.01 to $66.87 per share.
Proto Labs Chief Operations Officer Michael R. Kenison reported a tax-related share withholding transaction. On 02/10/2026, 2,684 shares of common stock were disposed of at $53.18 per share to cover tax obligations, leaving him with 31,842 shares of Proto Labs common stock held directly.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported routine equity compensation activity. On February 11, 2026, he exercised 3,135 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares and holding 43,971 shares directly afterward.
On February 10, 2026, 6,809 common shares were withheld at $53.18 per share to satisfy the exercise price or tax liabilities related to equity awards. All transactions are reported as direct ownership, and the option was noted as fully vested.
Proto Labs Inc. executive stock sale disclosed
Proto Labs Inc. Chief Operations Officer Michael R. Kenison reported selling 2,500 shares of common stock on February 6, 2026 at $60 per share. After this planned trade, he beneficially owns 34,526 shares of Proto Labs common stock.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Kenison adopted on August 15, 2025, which is designed to allow insiders to sell shares according to predetermined instructions.
Proto Labs, Inc. Chief Operations Officer Michael R. Kenison reported the acquisition of 8,128 shares of Proto Labs common stock on January 29, 2026, at a reported price of $0 per share. Following this transaction, he beneficially owns 37,026 shares of Proto Labs common stock in direct ownership, as disclosed in this Form 4 insider filing.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported acquiring additional company stock. On January 29, 2026, he acquired 20,686 shares of Proto Labs common stock at a reported price of $0 per share. Following this transaction, he directly beneficially owned 47,645 shares of Proto Labs common stock, as disclosed in this Form 4 insider filing.
Proto Labs Inc. Chief Operations Officer reported an amended insider transaction involving company common stock. On November 25, 2025, the officer exercised 3,048 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares. That same day, the officer sold 3,048 common shares at a weighted average price of $50.1741 per share under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025. After these transactions, the officer beneficially owned 28,898 common shares directly. The filing also clarifies that the stock options were fully vested and corrects the stated expiration date of the options to February 14, 2026, fixing a clerical error in a prior report while leaving all other transaction details unchanged.
Proto Labs, Inc. (PRLB) reported an insider transaction by its Chief Operations Officer on a Form 4. On 11/25/2025, the officer exercised an employee stock option for 3,048 shares of common stock at an exercise price of $33.84 per share, then sold 3,048 shares of common stock in open-market transactions at a weighted average price of $50.1741 per share. After these transactions, the officer directly beneficially owned 28,898 shares of Proto Labs common stock and held 4,664 employee stock options following the reported exercise. The filing notes that the trades were made under a Rule 10b5-1 trading plan adopted on August 15, 2025, and that the ownership total includes 57 shares acquired through the company’s employee stock purchase plan.
Proto Labs, Inc. (PRLB) reported an insider equity award for its Chief Technology & AI Officer on a Form 4. On 11/17/2025, the officer received 3,718 shares of common stock as a restricted stock unit grant at a price of $0, increasing direct beneficial ownership to 3,718 shares. The filing also reports a grant of an employee stock option for 6,818 shares of common stock with a $47.07 exercise price, expiring on 11/17/2035.
The restricted stock units vest annually over four years starting on November 15, 2026, and the stock option vests on the same schedule. This structure is designed so that the officer earns the awards gradually over time, which can help align long-term incentives with company performance and retention.